The right treatment for the right patient with COPD: lessons from the IMPACT trial

Abstract

Long-acting bronchodilators are the basis of treatment for COPD [1]; however, there are some patients who suffer from frequent or severe exacerbations, despite maximal bronchodilation [2]. These patients are at increased risk of death and represent a great challenge in clinical practice [3]. Inhaled corticosteroids (ICS) are the basis of the treatment of asthma and are also effective, albeit to a lesser extent, in some patients with COPD [4]. Generally speaking, ICS are indicated in patients with COPD and exacerbations, despite bronchodilator treatment [1]. Different patient characteristics have to be considered for prescription of triple therapy in COPD <https://bit.ly/2xWq7lW>

Topics & Concepts